Adherence to weight-loss drugs is far higher with Wegovy than older medicines

 Forty percent of patients who filled a prescription for Novo Nordisk's (NOVOb.CO) Wegovy to treat obesity in 2021 or 2022 were still taking it a year later, more than three times the rate of adherence with older medicines, according to an analysis of medical records and insurance claims data.